Spexis AG(SPEX)

Description: Spexis AG, a clinical-stage biopharmaceutical company, engages in discovering, developing, in-licensing, and acquiring molecules for rare diseases and cancer. Its products pipeline includes ColiFin, an inhaled colistimethate sodium product that is in the phase 3 trial for the treatment of cystic fibrosis (CF) infections; Inhaled Murepavadin, a novel class inhaled antibiotic which is in the phase 1 development stage to treat Pseudomonas aeruginosa infection in people with CF; EBX-002 for non-tuberculous mycobacterial lung infections; Balixafortide for oncology and non-oncology indications; New CXCR4 for treating orphan and hematological malignancies, and non-oncology indications; and Outer Membrane Protein Targeting Antibiotic BamA and lipopolysaccharide transport protein A programs. The company is headquartered in Allschwil, Switzerland.

---

Keywords: Cancer Biopharmaceutical Infection Rare Diseases Microbiology Bacteria Bacteriology Cystic Fibrosis Hematological Malignancies Gram Negative Bacteria Pseudomonas Pseudomonas Aeruginosa Treatment Of Cystic Fibrosis Pseudomonadales Colistimethate Sodium Colistin Cyclic Peptides

---

Home Page: spexisbio.com

Hegenheimermattweg 125
Allschwil, 4123
Switzerland
Phone: 41 61 567 16 00

---

Officers

Exchange: SW

Country: CH

Currency: Swiss Franc (CHF)